Back to top

Image: Bigstock

Danaher (DHR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Read MoreHide Full Article

For the quarter ended March 2026, Danaher (DHR - Free Report) reported revenue of $5.95 billion, up 3.7% over the same period last year. EPS came in at $2.06, compared to $1.88 in the year-ago quarter.

The reported revenue represents a surprise of -0.68% over the Zacks Consensus Estimate of $5.99 billion. With the consensus EPS estimate being $1.95, the EPS surprise was +5.92%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Total Growth - Organic sales (Core): 0.5% versus the five-analyst average estimate of 1.1%.
  • Total Sales- Diagnostics: $2.42 billion compared to the $2.47 billion average estimate based on three analysts. The reported number represents a change of -1.3% year over year.
  • Total Sales- Life Sciences: $1.74 billion versus $1.73 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.
  • Total Sales- Biotechnology: $1.8 billion versus $1.79 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.5% change.
  • Operating profit- Life Sciences: $225 million versus the two-analyst average estimate of $195.14 million.
  • Operating profit- Biotechnology: $534 million versus $513.28 million estimated by two analysts on average.
  • Operating profit- Other: $-89 million versus $-89.85 million estimated by two analysts on average.
  • Operating profit- Diagnostics: $674 million versus the two-analyst average estimate of $728.11 million.

View all Key Company Metrics for Danaher here>>>

Shares of Danaher have returned +2.9% over the past month versus the Zacks S&P 500 composite's +9.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' 7 Best Strong Buy Stocks (New Research Report)

Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.

Click Here, It's Really Free

Published in